Skip to main content
. 2022 Sep 9;14(18):4386. doi: 10.3390/cancers14184386

Figure 7.

Figure 7

Secondary assay for the primary SFRP1 mimetic hits analyzing activity as Wnt pathway antagonist. The Wnt-reporter cell line LEADING LIGHT® (Enzo Life Sciences, Farmingdale, NY, USA) expresses luciferase upon stimulation of the Wnt pathway after the addition of recombinant Wnt3a as a Wnt signaling ligand. Candidate SFRP1 mimetic hits might inhibit the Wnt signaling pathway at different levels, which should result in inhibition of the luciferase-induced luminescence.